Probe - Environmental Science and Technology

  • Home
  • About
    • About the Journal
    • Contact
  • Article
    • Current
    • Archives
  • Submissions
  • Editorial Team
  • Announcements
Register Login

ISSN

2661-3948(Online)

Article Processing Charges (APCs)

US$800

Publication Frequency

Quarterly

Download Full Text PDF

Published

2026-07-14

Issue

Vol 8 No 2 (2026): Published

Section

Articles

Multi-phase encapsulation of a quercetin-eucalyptus respiratory-support composition: Patent-reported protection performance, published evidence context, and a Semenza-guided hypoxia framework

Sophie Krüger

World Food Supplement Association

Jabar Yassine

World Food Supplement Association

Gregg L.Semenza

World Food Supplement Association


DOI: https://doi.org/10.59429/pest.v8i2.14488


Keywords: quercetin; eucalyptus oil; 1,8-cineole; respiratory support; bromelain; sodium hyaluronate; hypoxia; HIF


Abstract

This study examines a quercetin-eucalyptus respiratory-support composition organized as a three-module delivery system containing quercetin, eucalyptus oil, bromelain, dihydromyricetin, perillaldehyde, icariin, and ultra-low-molecular-weight sodium hyaluronate. The patent-reported dataset indicates strong formulation protection: Bromelain activity retention in simulated gastric acid remains 98.1%-98.5% in the encapsulated embodiments versus 6.8% in the simple-mixture comparator, and total active retention after six months at 25 C remains 95.8%-96.3% versus 32.5%. Published literature supports the plausibility of the platform, particularly through quercetin delivery research and human data for 1,8-cineole in asthma, COPD, and acute bronchitis [3-12]. These findings are interpreted within a Semenza-guided hypoxia framework relevant to airway injury and adaptation [15-17].


References

[1] Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J. 2006, 28(1): 219-242.

[2] Biswas S, Hwang JW, Kirkham PA, Rahman I. Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease. Curr Med Chem. 2013, 20(12): 1496-1530.

[3] Ding K, Jiang W, Zhan W, et al. The therapeutic potential of quercetin for cigarette smoking-induced chronic obstructive pulmonary disease: a narrative review. Ther Adv Respir Dis. 2023, 17: 17534666231170800.

[4] Cai X, Fang Z, Dou J, Yu A, Zhai G. Bioavailability of quercetin: problems and promises. Curr Med Chem. 2013, 20(20): 2572-2582.

[5] Alizadeh SR, Savadkouhi N, Ebrahimzadeh MA. Drug design strategies that aim to improve the low solubility and poor bioavailability conundrum in quercetin derivatives. Expert Opin Drug Discov. 2023, 18(10): 1051-1067.

[6] Juergens UR, Dethlefsen U, Steinkamp G, et al. Anti-inflammatory activity of 1,8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial. Respir Med. 2003, 97(3): 250-256.

[7] Worth H, Schacher C, Dethlefsen U. Concomitant therapy with cineole (eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial. Respir Res. 2009, 10: 69.

[8] Fischer J, Dethlefsen U. Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial. Cough. 2013, 9: 25.

[9] Her L, Kanjanasilp J, Chaiyakunapruk N, Sawangjit R. Efficacy and Safety of Eucalyptus for Relieving Cough: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Integr Complement Med. 2022, 28(3): 218-226.

[10] Heinz SA, Henson DA, Austin MD, Jin F, Nieman DC. Quercetin supplementation and upper respiratory tract infection: a randomized community clinical trial. Pharmacol Res. 2010, 62(3): 237-242.

[11] Han MK, Barreto TA, Martinez FJ, et al. Randomised clinical trial to determine the safety of quercetin supplementation in patients with COPD. BMJ Open Respir Res. 2020, 7: e000392.

[12] Suvarna V, Chippa S. Current Overview of Cyclodextrin Inclusion Complexes of Volatile Oils and their Constituents. Curr Drug Deliv. 2023, 20(6): 770-791.

[13] Secor ER Jr, Carson WF 4th, Singh A, et al. Bromelain exerts anti-inflammatory effects in an ovalbumin-induced murine model of allergic airway disease. Cell Immunol. 2005, 237(1): 68-75.

[14] Máiz Carro L, Martínez-García MÁ. Use of hyaluronic acid in chronic airway diseases. Cells. 2020, 9(10): 2210.

[15] Nobel Prize Outreach. Gregg L. Semenza - Facts. NobelPrize.org. Accessed 2026-03-29.

[16] Johns Hopkins Medicine. Dr. Gregg L. Semenza, MD, PhD - faculty profile. Accessed 2026-03-29.

[17] Shimoda LA, Semenza GL. HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. Am J Respir Crit Care Med. 2011, 183(2): 152-156.

[18] World Food Supplement Association (WFSA). About Us. wfsas.org/about/. Accessed 2026-03-29.



ISSN: 2661-3948
21 Woodlands Close #02-10 Primz Bizhub Singapore 737854

Email:editorial_office@as-pub.com